[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100633291":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":28,"locations":37,"responsibleParty":53,"collaborators":11,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":11,"eligibilityCriteria":63,"healthyVolunteers":59,"sex":64,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":11,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":11,"overallStatus":39,"whyStopped":11,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Zhejiang Cancer Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Sporoderm-removed Ganoderma lucidum spore powder (RGLS)","EXPERIMENTAL",null,[13],"Dietary Supplement: Sporoderm-removed Ganoderma lucidum spore powder (RGLS)",{"label":15,"type":16,"description":11,"interventionNames":17},"placebo group","PLACEBO_COMPARATOR",[18],"Other: Placebo",[20,24],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":11},"DIETARY_SUPPLEMENT","From the first day after enrollment, subjects take RGLS orally at 4g\u002Fday for 3 months.",[9],{"type":6,"name":25,"description":26,"armGroupLabels":27,"otherNames":11},"Placebo","From the first day after enrollment, subjects take placebo orally at 4g\u002Fday for 3 months.",[15],[29,34],{"name":30,"role":31,"phone":32,"phoneExt":11,"email":33},"Zhiqiang Ling","CONTACT","+86-571-88122423","lingzq@zjcc.org.cn",{"name":35,"role":31,"phone":11,"phoneExt":11,"email":36},"Jinbiao Shang","shangjb@zjcc.org.cn",[38],{"facility":5,"status":39,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"RECRUITING","Hangzhou","Zhejiang","310022","China","CN",{"type":46,"coordinates":47},"Point",[48,49],120.16142,30.29365,{"lat":49,"lon":48},[52],{"name":30,"role":31,"phone":32,"phoneExt":11,"email":33},{"type":54,"investigatorFullName":55,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"SPONSOR_INVESTIGATOR","Ling Zhiqiang","Prof., M.D., PhD,","100633291","ganoderma-spores-modulate-the-gut-brain-axis-100633291",false,"NCT07524777","Ganoderma Spores Modulate the Gut-Brain Axis","Targeting the Gut-Brain Axis With Ganoderma Lucidum Spores Ameliorates Depression in Thyroid Cancer Patients: a Randomized, Double-blind, Placebo-controlled Trial","Inclusion Criteria:\n\n* Outpatients at Zhejiang Cancer Hospital with histologically confirmed papillary thyroid carcinoma (post-surgery) and depressive symptoms (HAMD-24 score ≥ 8, confirmed by a clinical psychologist).\n* Han Chinese ethnicity.\n* No history of depression or other psychiatric disorders.\n* Age 18-80 years.\n* Female.\n\nExclusion Criteria:\n\n* Suffering from other gastrointestinal system diseases.\n* History of gastrointestinal surgery prior to intervention.\n* Including those with other concurrent malignancies requiring chemotherapy, radiotherapy, biological therapy, or traditional Chinese medicine treatment.\n* Received antibiotic treatment or microecological modulators within 3 months prior to intervention.\n* Acute intestinal obstruction.\n* Patients who are currently taking antidepressant medication, or those whom the investigators judge require immediate initiation of antidepressant medication treatment.\n* Organic brain diseases, brain trauma.\n* History of psychiatric disorders, use of psychoactive substances (e.g., drugs).\n* Severe liver or kidney dysfunction.\n* Pregnancy or lactation.","FEMALE","18 Years","80 Years",{"count":68,"type":69},300,"ESTIMATED","INTERVENTIONAL",[72],"NA","This study aims to investigate whether Sporoderm-removed Ganoderma lucidum spore powder (RGLS) ameliorates depression in thyroid cancer patients through gut-brain axis modulation, and to elucidate the underlying microbial and metabolic mechanisms. This 3-month randomized, double-blind, placebo-controlled trial will enroll 300 postoperative papillary thyroid carcinoma patients with depressive symptoms (HAMD-24 ≥ 8). Participants will be randomly assigned(2 : 1) to receive RGLS (4 g\u002Fday) or matched placebo.",[75,76],"Depression","Thyroid Cancer","2026-05-07",{"date":79,"type":80},"2026-05-12","ACTUAL",{"date":82,"type":80},"2026-04-11",{"date":84,"type":69},"2026-08-31",{"name":55,"class":6},1]